No Data
Sanofi Signs Deal for Greater China Rights to Aficamten
Sanofi's Tolebrutinib Receives FDA Breakthrough Therapy Designation for NrSPMS
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi
Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China